A MedTech using physics to treat brain tumours has won a grant from Innovate UK.
QV Bioelectronics, creator of a surgically implanted electric field therapy device, has been awarded £860,000 under the Combined Investor Partnerships Award following its £2 million pre-Series A fundraising round in January.
It takes the total amount of grant funding awarded to QV to £1.8m, which includes an ongoing Innovate UK Biomedical Catalyst Award and previous support from the National Institute for Health Research (NIHR) and Innovate UK SMART.
QV Bioelectronics’ implant GRACE is currently in pre-clinical development. The first-of-its-kind technology aims to target dividing cancer cells within the brain without affecting healthy cells.
The first clinical indication for GRACE will be the most aggressive and deadly primary brain tumour, Glioblastoma (GBM), which has some of the worst outcomes of any cancer.
QV Bioelectronics is led and co-founded by biomedical engineer Dr Christopher Bullock (CEO) and Dr Richard Fu, a specialty registrar in neurosurgery and brain cancer researcher in the NHS.
“We are delighted to have been awarded the Investor Partnerships Award,” said Dr Bullock. “This award, alongside our latest funding round, will be instrumental in accelerating the development of GRACE.
“This technology has the potential to revolutionise cancer treatment, and we are thrilled to have Innovate UK’s backing as we work towards making a real difference in the lives of those affected by this devastating disease.”